Genentech Oncology
Investigational Therapies
These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.
Showing 84 out of 84 results
Phase III
Breast
Gastrointestinal
Hematology
Lung
Phase II
Gastrointestinal
Hematology
Lung
Melanoma
Solid Tumor
Phase I
Brain
Breast
Gastrointestinal
Genitourinary
Gynecologic
Head Neck
Hematology
Lung
Melanoma
Solid Tumor
aDeveloped in collaboration with Array Biopharma. bDeveloped in collaboration with Exelixis. cJoint project with AbbVie. dManaged by Repare Therapeutics. eDeveloped in collaboration with Relay Therapeutics. fDeveloped in collaboration with Chugai. gDeveloped in collaboration with Xencor. hManaged by Poseida Therapeutics.
Current as of May 10, 2023. The trial information is taken from ClinicalTrials.gov.
-
-
Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf
Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf
-
-